QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI — Collection, Management and Submission of ICSRs

Test your understanding of the concepts covered by GVP Module VI: Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A social-media post states that a named individual experienced a rash after taking a product, but there is no identifiable source who can be contacted. What is the appropriate next step?

Automatically classify it as a valid ICSR because it appears online Apply the applicable validity criteria, including assessment of source and patient identifiability Ignore all digital information because social media cannot support pharmacovigilance Submit it immediately without assessing whether it concerns an individual case

Question 2 of 10 Why should duplicate detection continue after initial case entry?

Because duplicates can arise or become recognisable when additional reports and information are received Because initial validation is never permitted to identify duplicates Because every follow-up must create a second case for comparison Because duplicate detection is required only for serious cases

Question 3 of 10 What is the primary purpose of reconciliation between an internal safety database and a regulatory gateway?

To replace medical review with an automated comparison To identify discrepancies, losses, duplications or transmission problems across the interface To determine whether every event is causally related to the product To eliminate the need for submission acknowledgements

Question 4 of 10 Which statement best captures the overall control-system model for ICSR management?

Reliable database technology alone is sufficient The process requires effective input, processing, output, error detection and oversight layers Medical review is the only control layer that affects case quality Regulatory submission is separate from case processing and does not require reconciliation

Question 5 of 10 A system generates an electronic ICSR message, but the regulatory gateway later rejects it. Which conclusion is most appropriate?

The case is successfully submitted because message generation is sufficient The organisation must assess the rejection, correct the problem and manage resubmission while considering the applicable timeline The rejection has no significance if the internal database contains the case The case should be closed immediately to prevent repeated transmission

Question 6 of 10 An MAH outsources case processing to a vendor. Which responsibility remains with the MAH?

None, once the contract has been signed Oversight of receipt, timelines, quality, reconciliation, escalation and vendor performance Only responsibility for the vendor's employee training records Responsibility only for cases that the vendor fails to process

Question 7 of 10 Which situation presents the greatest risk of an avoidable regulatory reporting delay?

A processor takes time to write a concise narrative after timely case creation A safety message enters a shared mailbox that is not connected to pharmacovigilance monitoring A case receives a documented medical review before submission A follow-up request is prioritised according to seriousness

Question 8 of 10 Which combination most accurately describes key dimensions of ICSR data quality?

Completeness, accuracy, consistency, timeliness and traceability Speed, volume, profitability, automation and staffing Seriousness, expectedness, causality, frequency and product sales Narrative length, reporter seniority, database size, coding speed and cost

Question 9 of 10 A case is marked operationally closed after all current processing activities are complete. Which control principle still applies?

Closure means the case can never be updated The system should allow later reopening or updating if new information is received Closed cases should be deleted to prevent duplicate processing Only the original reporter may reopen a closed case

Question 10 of 10 Which statement best distinguishes regulatory seriousness from clinical severity?

They are interchangeable because any clinically severe event is regulatory serious Regulatory seriousness is determined by applicable seriousness criteria, not solely by how severe an event appears clinically Clinical severity is used only for literature cases Regulatory seriousness can be assigned only by the original reporter

Knowledge Assessment: GVP Module VI — Collection, Management and Submission of ICSRs

Cookie Settings